HY26 Trading Update
Strong commercial momentum drives more than doubling of orderbook
“I am pleased to report renewed commercial momentum in the first half of 2026, with one of our strongest periods of new contract sales to date. This has more than doubled our orderbook since the start of the year, providing improved revenue visibility for the remainder of 2026, 2027 and into 2028. As previously guided, revenue in 2026 is expected to be weighted to the second half with a broad mix of contracted business scheduled to commence over the coming months."
“We have made good progress executing our strategy, now operating under one brand across Consulting, Clinical
Trials, Human Challenge Trials and Laboratory Services - together supporting stronger commercial activity. This diversified model will support a more balanced and resilient revenue profile and positions the Group well for sustainable future growth.”
Yamin 'Mo' Khan
CEO at hVIVO
Our Purpose
Accelerate the development of safe and effective medicines that improve the lives of people around the world.
Our Mission
To constantly pursue new ways to reduce the time, risk and cost of bringing much needed life-changing medicines to market
hVIVO plc Annual Report & Accounts 2025
Download and read the 2025 Annual Report
